|This will be the third presentation this month. Company is working hard! BOSTON , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc , (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time .|
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals , with headquarters in Boston , is focused on bringing innovative medicines to people with renal disease. In December 2014 , the company launched its first FDA -approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014 , ferric citrate was approved for use in Japan , where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015 , the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
Re: From Chris Lau in Valuestocks "...Kerx Biopharmaceuticals Will Rebound,
*****I am writing drunk*****
| Reply to SpecGuru - Msg #2637803 - 09/21/2016 15:27|
From Chris Lau in Valuestocks "...Kerx Biopharmaceuticals Will Rebound,
Kerx Biopharmaceuticals looks cheaply valued at these levels. The company expanded its sales team to 95 FTEs, up from 60 in 2014. Expect revenue inflecting upwards from here.
The sales team is working closely with clinicians. Even though a supply disruption will hurt Auryxia sales near-term, management is re-calibrating the manufacturing process to restore output. By fourth quarter, supply levels should return to normal.
The payer access should sustain revenue levels. From its presentation at the Biard global healthcare conference, Kerx said:
“On the payer front, we have access now to majority of patients taking phosphate binders across all Part D and commercials and we continue to see very good pay claim rates at pharmacies when patients still in pharmacy with prescription of Auryxia, the vast majority of those patients are getting that still for $110.”
Kerx may potentially expand Auryxia’s reach in the marketplace. By addressing iron deficiencies for patients, Kerx’s market may more than double.
In the fourth quarter, Kerx has a potential catalyst. A successful application for making the drug available to dialysis patients would boost the stock price. Expanding the indications for the treatment of iron deficiency anaemia is possible. Its success is based on results for its Phase 3 trial completed earlier this year. Re: Not boring, isn't it? :-)Re: GO!!!Re: Buy up to $7.00 for a double digit gain...